Viemed Healthcare, Inc.
HealthcareNASDAQ:VMD · NASDAQ Capital Market
+$0.03 today
Vol 0.20M · Avg 0.27M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
10.6%
avg 22.9%
ROIC
8.3%
avg 18.8%
ROA
6.9%
avg 14.3%
Analysis
ROE is currently the strongest return metric at 10.6% versus its period average of 22.9%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Casey Hoyt | Chief Executive Officer & Director | $1.11M | — | 49 | $350,464.00 | 0.91% |
Michael Moore | President | $973,488.00 | — | 49 | $1.59M | 4.14% |
William Todd Zehnder | Chief Operating Officer & Director | $967,909.00 | — | 51 | $8,946.00 | 0.02% |
Jerome Richard Cambre | Vice President of Sales | $553,003.00 | — | 55 | $106,961.00 | 0.28% |
Jeremy Trahan | Executive VP, General Counsel & Corporate Secretary | $539,411.00 | — | 56 | $50,083.00 | 0.13% |
Trae Paul Fitzgerald | Chief Financial Officer | $507,848.00 | — | 38 | $108,903.00 | 0.28% |
William Dana Frazier | Chief Medical Officer & Director | $53,044.00 | — | 68 | $8,946.00 | 0.02% |
Michael Freeman | Chief Business Development Officer | — | — | — | $1.59M | 4.14% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
12
$3.25M
Net Sentiment
$3.25M
Net selling
Most Active
Moore Michael
7 transactions
1–10 of 12
Analysis
Insiders reported 0 buys worth $0.00 and 12 sells worth $3.25M over the last 12 months. That adds up to net selling of $3.25M. Moore Michael was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -44.1% | +12.6% (10yr)1 analysts |
| Revenue | N/A | N/A | +23.6% | +20.4% (10yr)2 analysts |
| Net Income | N/A | N/A | +4.5% | +13.1% (10yr)2 analysts |
| EBIT | N/A | N/A | +19.3% | +7.4% (10yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +23.6% over three years. Forward estimates point to Revenue at +20.4% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
908 Devices Inc.
NASDAQ:MASS
$312.72M
Electromed, Inc.
AMEX:ELMD
$307.52M
Senseonics Holdings, Inc.
NASDAQ:SENS
$299.93M
Sight Sciences, Inc.
NASDAQ:SGHT
$279.12M
Inogen, Inc.
NASDAQ:INGN
$173.28M
Quanterix Corporation
NASDAQ:QTRX
$146.03M
CVRx, Inc.
NASDAQ:CVRX
$133.48M
SANUWAVE Health, Inc.
NASDAQ:SNWV
$128.21M
Nano-X Imaging Ltd.
NASDAQ:NNOX
$122.48M
Outset Medical, Inc.
NASDAQ:OM
$83.23M
Who manages VMD?
Viemed Healthcare, Inc. (VMD) lists 8 active executives. The top listed executive is Casey Hoyt, Chief Executive Officer & Director.
Are VMD insiders buying or selling?
Recent insider activity shows net selling of $5.58M.
Explore More
Continue the stock analysis
Jump to another research area for this company.